{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.6","upperLimit":"85.7","value":"77.6"},{"groupId":"OG001","lowerLimit":"70.1","upperLimit":"87.7","value":"80.0"},{"groupId":"OG002","lowerLimit":"67.2","upperLimit":"85.4","value":"77.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"description":"VGPR or better rate was defined as the percentage of participants who achieved VGPR or CR (including sCR) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \\>= 90% reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \\<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1, then on Days 1 and 22 in Cycles 2 to 9, and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months; bortezomib 1.3 mg/m\\^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m\\^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m\\^2 orally on Days 1 to 4 of cycles 1 to 9.","id":"OG000","title":"D + Bortezomib + Melphalan + Prednisone (D-VMP)"},{"description":"Participants received daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2, then on Day 1 and 15 of Cycles 3 to 6, and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months.","id":"OG001","title":"Daratumumab + Lenalidomide + Dexamethasone (D-Rd)"},{"description":"Participants received daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days), then on Day 1 and 15 of Cycles 3 to 6, and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months; Carfilzomib 20 mg/m\\^2 IV on Day 1 of Cycle 1 only, then 70 mg/m\\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months and dexamethasone 40 mg orally or IV weekly for Cycles 1-9, then on Days 1, 8, 15 of each cycle for Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months.","id":"OG002","title":"Daratumumab + Carfilzomib + Dexamethasone (D-Kd)"}],"paramType":"NUMBER","populationDescription":"All treated analysis set included all participants who have received at least 1 dose of study treatment. This secondary OM was planned to be analyzed for D-VMP, D-Rd and D-Kd cohorts only.","reportingStatus":"POSTED","timeFrame":"From baseline up to 2 years 7 months","title":"D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With VGPR or Better Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}